SLDB Solid Biosciences Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1707502 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-28.8%
TTM EPS YoY29.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-76.9%
ROA-64.9%
ROIC (approx.)-94.0%
Asset turnover—
Leverage & solvency
Liabilities / assets12.3%
Debt / equity0.00x
Current ratio11.99x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.92x
Accruals ratio-4.9%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY2025*2025-12-31 | FY2024*2024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | — | — |
| R&D expense | $140.32M | $96.43M |
| SG&A expense | $38.88M | $33.30M |
| Operating income | -$179.21M | -$129.73M |
| Interest expense | -$203,000 | $340,000 |
| Pretax income | -$174.20M | -$124.58M |
| Income tax | $0 | $0 |
| Net income | -$174.32M | -$124.70M |
| EBITDA | -$177.57M | -$127.27M |
| EPS (basic) | -1.99 | -3.06 |
| EPS (diluted) | -1.99 | -3.06 |
| Weighted avg. shares (diluted) | 87.50M | 40.82M |
| Balance sheet | ||
| Cash & equivalents | $59.90M | $82.19M |
| Short-term investments | $127.95M | $68.69M |
| Current assets | $205.46M | $157.30M |
| PP&E, net | $4.17M | $4.75M |
| Total assets | $232.54M | $188.66M |
| Current liabilities | $33.47M | $30.26M |
| Total liabilities | $52.53M | $51.42M |
| Shareholders' equity | $180.01M | $137.25M |
| Shares outstanding | 78.97M | 40.47M |
| Cash flow statement | ||
| Operating cash flow | -$156.29M | -$100.01M |
| Capital expenditure | $1.15M | $654,000 |
| Free cash flow | -$157.44M | -$100.67M |
| Investing cash flow | -$58.45M | -$16.09M |
| Financing cash flow | $194.45M | $122.44M |
| Depreciation & amortization | $1.64M | $2.46M |
| Stock-based compensation | $16.91M | $10.52M |
Free plan shows the latest 2 periods; Pro shows all 10 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.